Current Report Filing (8-k)
July 16 2020 - 7:42AM
Edgar (US Regulatory)
0000001800
false
Common Shares, Without Par Value
ABT
0000001800
2020-07-16
2020-07-16
0000001800
us-gaap:CommonStockMember
exch:XCHI
2020-07-16
2020-07-16
0000001800
us-gaap:CommonStockMember
exch:XNYS
2020-07-16
2020-07-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Common Shares, Without Par Value
|
|
ABT
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
July 16, 2020
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in
charter)
Illinois
|
|
1-2189
|
|
36-0698440
|
(State or other Jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification No.)
|
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number, including
area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of
the Act:
Title of Each Class
|
Trading
Symbol(s)
|
Name of Each Exchange
on Which Registered
|
Common Shares, Without Par Value
|
ABT
|
New
York Stock Exchange
Chicago
Stock Exchange, Inc.
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02
|
Results of Operations and Financial Condition
|
On July 16, 2020, Abbott Laboratories announced its results
of operations for the second quarter 2020.
Furnished
as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results.
In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations
excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as
expenses primarily associated with acquisitions and restructuring actions, charges related to cost reduction initiatives, the acquisition
of R&D assets, charges related to impairment of certain assets, and tax benefits associated with specified items, a reduction
in the transition tax associated with the Tax Cuts and Jobs Act, tax benefits associated with the resolution of various tax positions
related to prior years and excess tax benefits associated with share-based compensation. These non-GAAP financial measures
also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs,
similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation
of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as
these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management
also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions
investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared
in accordance with GAAP.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABBOTT LABORATORIES
|
|
|
|
|
Date: July 16, 2020
|
By:
|
/s/ Robert E. Funck, Jr.
|
|
|
Robert E. Funck, Jr.
|
|
|
Executive Vice President, Finance
and Chief Financial Officer
|
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Apr 2023 to Apr 2024